PDS Biotechnology Corp (PDSB)

[Fress]

Oppenheimer gave an over weight buy target at $7.00 last month.


Chardan Capital Reiterated Rating Buy $10.00


Alliance Global Partners Boost Price Target Buy $6.50


Noble Financial Reiterated Rating Buy $6.60


HC Wainwright Upgrade from Neutral to Buy $6.00

PDSB is partnered with the three top cancer institutes in the world. And Merck one of the biggest biotech companies in the world.

1)The University of Texas MD Anderson Cancer Center (colloquially MD Anderson Cancer Center) is a comprehensive cancer center in Houston, Texas. It is the largest cancer center in the US and one of the original three comprehensive cancer centers in the country.
https://www.mdanderson.org/


2)The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. Our team of approximately 3,500 is part of the National Institutes of Health (NIH), one of 11 agencies that make up the Department of Health and Human Services (HHS)
https://www.cancer.gov/about-nci


3)The National Institute of Allergy and Infectious Diseases is one of the 27 institutes and centers that make up the National Institutes of Health, an agency of the United States Department of Health and Human Services.
https://www.niaid.nih.gov/


65 million market cap 34 million cash funded through mid 2022.

debt free.

22 million shares 11 floating 45% held now by institutions and insiders.

PDSB is a billion dollar company in the making second generation oncology and infectious disease platforms.


1.Development of PDS0203 - A second generation COVID-19 vaccine that
promotes powerful T-cell responses and neutralizing antibodies.

2. Phase 1 clinical trial: Powerful in-vivo CD8+ T-cell response results in
regression of CIN cervical lesions – supports preclinical studies.
Overcomes key limitation of immuno-oncology: > 20-fold increase in circulating dual INF-? & Granzyme-b
inducing killer T-cells vs. pre-treatment at day 14 led to rapid clearance of lesions*

3. Greater quantity and quality of Versamune®-induced killer T-cells may result in unique ability to eradicate HPV-positive tumors after a single dose.
Induced a >10-fold number of highly potent T-cells and eradication of HPV-positive tumors after a single dose.

4.Versamune® possesses the key characteristics of a safe and effective immunotherapeutic treatment.
A.Induction of high levels of active
CD8+ (killer) T-cells.
B.Induction of high levels of CD4+
(helper) T-cells.
C.Ability to overcome tumor immune
suppression.
D.Induction of long-term memory CD8+
T-cells.


Monster move coming VIR & GRTS T cell platforms had made monster strides. PDSB cutting edge VERSAMUNE® PLATFORM will have its day of reckoning sooner than later. You can make book on that.




January 2021 PDSB biz presentation:
https://www.pdsbiotech.com/images/pdf/presentation/2021/PDSB_Corporate_Overview_-_Jan_2021_FINAL-1.pdf

PDSB website:
https://www.pdsbiotech.com/

$PDSB